drugset / Trial / NCT00235391
Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open-label, non-randomized, multi-center trial designed to provide expanded access of deferasirox to patients with congenital disorders of red blood cells and chronic iron overload from blood transfusions who cannot adequately be treated with locally approved iron chelators.
Timeline
- Start
- 2005-10
- Primary completion
- 2008-10
- Completion
- 2008-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Deferasirox | Unknown | 10 mg/kg | Oral |
| Subject | Deferasirox | Unknown | 20 mg/kg | Oral |
| Subject | Deferasirox | Unknown | 30 mg/kg | Oral |